Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder A 52-week Extension to: A Phase IIb Randomized, Placebo- and Active Comparator (Tolterodine)-Controlled, 2-Part Clinical Study of the Efficacy and Safety of MK-4618 in Patients With Overactive Bladder
Brief Summary: This is a 2-part study to assess if vibegron (MK-4618) reduces the number of daily urinations more effectively than placebo in participants with overactive bladder (OAB). The primary hypothesis of the base study is that administration of vibegron demonstrates a dose-related reduction, compared with placebo, in average number of daily micturitions in participants with OAB after 8 weeks of treatment.


Options:
A: Intervention Type: DRUG; Name: Tolterodine ER 4mg QD; Assigned to Arm(s): N/A
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Solifenacin 5 mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: solifenacin | Arm Label: Solifenacin 10 mg; Type: EXPERIMENTAL; Interventions: Drug: solifenacin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Solifenacin 5 mg | Intervention Type: DRUG; Name: solifenacin; Assigned to Arm(s): Solifenacin 10 mg, Solifenacin 5 mg
C: Arm Label: TROSPIUM CHLORIDE; Type: ACTIVE_COMPARATOR; Interventions: Drug: Trospium Chloride | Arm Label: PLACEBO; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Trospium Chloride; Assigned to Arm(s): TROSPIUM CHLORIDE | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): PLACEBO
D: Arm Label: Part 1: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 3 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 15 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: vibegron 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 1: tolterodine ER 4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER, Drug: Placebo matching vibegron | Arm Label: Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Tolterodine ER, Drug: Placebo matching tolterodine ER | Arm Label: Part 2: placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 2: vibegron 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Part 2: tolterodine ER 4 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: Tolterodine ER, Drug: Placebo matching vibegron | Arm Label: Part 2: vibegron 100 mg + tolterodine ER 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Tolterodine ER | Arm Label: Extension Study: vibegron 50 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Extension Study: vibegron 100 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Placebo matching tolterodine ER | Arm Label: Extension Study: tolterodine ER 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Tolterodine ER, Drug: Placebo matching vibegron | Arm Label: Extension Study: vibegron 100 mg + tolterodine ER 4 mg; Type: EXPERIMENTAL; Interventions: Drug: Vibegron, Drug: Tolterodine ER | Intervention Type: DRUG; Name: Vibegron; Assigned to Arm(s): Extension Study: vibegron 100 mg, Extension Study: vibegron 100 mg + tolterodine ER 4 mg, Extension Study: vibegron 50 mg, Part 1: vibegron 100 mg, Part 1: vibegron 15 mg, Part 1: vibegron 3 mg, Part 1: vibegron 50 mg, Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg, Part 2: vibegron 100 mg, Part 2: vibegron 100 mg + tolterodine ER 4 mg | Intervention Type: DRUG; Name: Tolterodine ER; Assigned to Arm(s): Extension Study: tolterodine ER 4 mg, Extension Study: vibegron 100 mg + tolterodine ER 4 mg, Part 1: tolterodine ER 4 mg, Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg, Part 2: tolterodine ER 4 mg, Part 2: vibegron 100 mg + tolterodine ER 4 mg | Intervention Type: DRUG; Name: Placebo matching vibegron; Assigned to Arm(s): Extension Study: tolterodine ER 4 mg, Extension Study: vibegron 50 mg, Part 1: placebo, Part 1: tolterodine ER 4 mg, Part 1: vibegron 15 mg, Part 1: vibegron 3 mg, Part 1: vibegron 50 mg, Part 2: placebo, Part 2: tolterodine ER 4 mg | Intervention Type: DRUG; Name: Placebo matching tolterodine ER; Assigned to Arm(s): Extension Study: vibegron 100 mg, Extension Study: vibegron 50 mg, Part 1: placebo, Part 1: vibegron 100 mg, Part 1: vibegron 15 mg, Part 1: vibegron 3 mg, Part 1: vibegron 50 mg, Part 1: vibegron 50 mg + tolterodine ER 4 mg/vibegron 50 mg, Part 2: placebo, Part 2: vibegron 100 mg

Answer: D